Nebivolol is a beta-blocker. It works by affecting the response to nerve impulses in certain parts of the body, like the heart. As a result, the heart beats slower and decreases the blood pressure. When the blood pressure is lowered, the amount of blood ejected per beat is reduced, lowering myocardial oxygen demand and cardiac workload. Nebivolol combines high beta1 receptor selectivity with endothelium dependent vasodilatory properties that are mediated through enhanced nitric oxide bioavailability. The compound is well absorbed after oral dosing but undergoes variable first pass metabolism primarily via CYP2D6, producing active metabolites; apparent elimination half life varies with metabolizer status, supporting once daily dosing. Clinically relevant effects include reduction in heart rate, decrease in cardiac output and a fall in systemic vascular resistance, with a favorable metabolic profile compared with some older beta-blockers.
Parent: Nebivolo
Nebivolo active pharmaceutical ingredient is manufactured and controlled to typical pharmaceutical API standards. Typical specification targets are assay 98.0 to 102.0 percent w by w, total impurities not greater than 1.0 percent w by w, and any individual unspecified impurity not greater than 0.20 percent w by w. Specified related compounds such as stereoisomeric forms, expected oxidative or dealkylated process impurities and defined synthetic intermediates are usually limited to 0.50 percent w by w or lower per impurity. Residual solvents meet ICH Q3C class limits, heavy metals are controlled to pharmacopeial levels and water content is minimized consistent with hygroscopic profile. Potential genotoxic impurities are assessed and controlled in line with ICH M7 thresholds and qualification is performed when impurity levels approach reporting thresholds defined by maximum daily dose.
Nebivolol is used to treat hypertension and to reduce heart rate and myocardial workload in appropriate cardiac conditions. It lowers blood pressure by blocking beta1 adrenergic receptors in the heart and by producing nitric oxide mediated vasodilation, which together reduce cardiac output and systemic vascular resistance. Prescribing depends on individual cardiovascular status and comorbidities.
Nebivolol may not be preferred when guideline recommended first line agents for a specific patient profile are ACE inhibitors, angiotensin receptor blockers, calcium channel blockers or thiazide diuretics. It can be less suitable for patients with sinus bradycardia, advanced atrioventricular block, decompensated heart failure, or severe reactive airway disease. Drug interactions, especially with strong CYP2D6 inhibitors, and clinician familiarity or formulary availability can also influence preference.
Nebivolol is typically prescribed once daily; the best time is the same time each day to maintain steady plasma levels. Many patients take it in the morning to cover daytime blood pressure and reduce the chance of nocturnal bradycardia, but dosing can be adjusted by the prescriber based on blood pressure pattern and tolerability. It may be taken with or without food.
Nebivolol is not inherently high risk when used according to prescribing information and with appropriate monitoring, but it carries known risks typical of beta blockers including symptomatic bradycardia, hypotension, worsening of conduction defects, and potential exacerbation of bronchospastic disease. Abrupt withdrawal can precipitate angina or hypertension, so tapering may be required. Risk assessment should be individualized by the treating clinician.
